HOME >> MEDICINE >> NEWS
Drug combination boosts survival rate in head and neck cancers

ORLANDO, Fla.--Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. The findings will be presented at the American Society of Clinical Oncology's annual meeting.

Previous studies have shown that using combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). Robert Haddad, MD, and his colleagues found that adding the drug docetaxel (Taxotere) to the cisplatin and 5-fu regimen significantly increased the complete pathological response rate to 89 percent. The data (Abstract 5511) will be presented as a poster discussion session on Saturday, May 14, at 1 p.m., Level 4, 414.

Using data obtained from treating 72 patients with locally advanced squamous cell carcinoma of the head and neck, the researchers project that the three-drug combination would result in a 95 percent two-year survival rate and a 90 percent five-year survival rate. The majority of these patients have stage IV disease.

"These results are very encouraging and in all likelihood will translate into a significantly more effective treatment for patients with advanced head and neck cancer," says Haddad. "This patient population historically has had a poor prognosis, but, given these findings, the outlook is more hopeful."

The drug combination is given for three cycles as an initial treatment, known as induction chemotherapy, to shrink tumors prior to several weeks of intense treatment with additional chemotherapy given along with radiation. This "sequential therapy" has brought about the most successful results in patients with these stubborn cancers. Cancers of the head and neck are diagnosed in more than 40,000 people in the United States each year, with about 7,200 deaths.

Based on recent results of Phas
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
14-May-2005


Page: 1 2

Related medicine news :

1. Phase II study shows combination improves survival of metastatic melanoma patients
2. Certain combination therapy found more effective for treating malaria in African children
3. To get blood pressure under control, combination of medicines may be best
4. Drug/intervention combinations offer benefit in severe CVD
5. Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
6. Drug combination slows progression of treatment resistant bone marrow cancer
7. Drug combination proves effective against myeloma in Phase I trial
8. Drug combination could reduce risk of severe asthma attacks
9. Transplant patients keep their new kidney longer with a CellCept-based drug combination
10. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
11. New combination therapy after surgery improves survival for pancreatic cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2020)... MILFORD, Pa. (PRWEB) , ... February 20, 2020 , ... ... Cosmetic Dermatology Surgery & Laser Center in Milford, Penn requesting treatments to achieve “ ... 2019. And it doesn’t look like it is slowing down into 2020. It’s a ...
(Date:2/19/2020)... ... February 19, 2020 , ... Actor, director, and producer, ... known for his acting abilities demonstrated in blockbuster hits like the “John Wick” ... Scenes” with Laurence Fishburne. “Behind The Scenes” features a broad array of topics. ...
(Date:2/19/2020)... ... February 19, 2020 , ... SEAL SHIELD, LLC - ... result of healthcare-acquired infections (HAIs.) According to The Centers for Disease Control (CDC), 80% ... large amount of screens that are now acting as an extension of people’s hands, ...
(Date:2/15/2020)... ... 14, 2020 , ... Sister companies, Special Learning Inc. and ABA Business Growth, ... The series explores the challenges, risks, and opportunities of private equity investment and acquisition ... 2020 at: https://bit.ly/2OU6lxg , Since 2010, more than 60 private equity ...
(Date:2/14/2020)... ... February 14, 2020 , ... “The American Society for ... texture and discoloration, and lines and wrinkles. And the treatments they are most ... great specials in February specifically to address the areas our patients are most ...
Breaking Medicine News(10 mins):
(Date:2/19/2020)... ... ... Aspire Regenerative, a leader in offering therapies that restore healthy tissues in ... event on March 1, 2020. It will take place from 10:30 a.m. to 1:30 ... the event, physicians and pharmacists will lead an informative and insightful discussion on weight ...
(Date:2/19/2020)... Moorsetown, NJ (PRWEB) , ... February 19, 2020 , ... ... “Composite Artistry Simplified” on March 20, 2020 at The Mansion in Voorhees. The course ... whole, and when placing dental implants. Dental implants, including All-on-4® full ...
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 Foundation, ... medicine for everyone affected by diabetes, announced a partnership with VeloCity, a fundraising ride ... third annual VeloCity event takes place on May 2nd and begins on the Mercedes-Benz ...
Breaking Medicine Technology:
Cached News: